SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway: SREBP2 Inhibitor sensitizes HCC to lenvatinib

Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular cholesterol levels are associated with tyrosine kinase inhibitor (TKI) efficacy. Here, we...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Acta biochimica et biophysica Sinica 2023-07, Vol.55 (9), p.1479-1486
Hauptverfasser:	Fan, Minghao, Chen, Zhenmei, Shao, Weiqing, Chen, Yiran, Lin, Zhifei, Yi, Chenhe, Li, Yitong, Lu, Lu, Zhou, Yu, Lin, Jing
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!